Top Story

Yale Cancer Center names director, physician in chief

Yale Cancer Center names director, physician in chief
October 25, 2016

Charles S. Fuchs, MD, has been named director and physician in chief at Smilow Cancer Hospital at Yale New Haven.

Fuchs — whose appointment takes effect Jan. 1 — most recently served as professor of medicine at Harvard Medical School, as well as chief of the gastrointestinal oncology division and chair of pancreatic cancer at Dana-Farber Cancer Institute.

In the Journals

Fecal immunochemical test a good option for colorectal cancer prevention

October 24, 2016
Noninvasive fecal immunochemical testing is an effective alternative to colonoscopy and stool blood-based screening methods for colorectal cancer screening, according to…
In the Journals Plus

Ibrutinib shows promise for advanced CLL with 17p deletion

October 24, 2016
Ibrutinib induced a high overall response rate and demonstrated a favorable safety profile in patients with relapsed or refractory chronic lymphocytic leukemia with 17p…

How would Clinton or Trump impact the country's health care system?

October 24, 2016
Two separate analyses completed by the Commonwealth Fund and an economist at the Rand Corporation of proposed health care plans from Hillary Clinton and Donald Trump…
In the Journals

Melanoma-associated leukoderma may be misdiagnosed as vitiligo

October 24, 2016
Experts frequently misdiagnosed melanoma-associated leukoderma as vitiligo in a blinded assessment, according to study results recently published in the Journal of the
More News Headlines »
CME Video

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Meeting News Coverage

VIDEO: Thyroid imaging approaches not ‘one-size fits all’

September 23, 2016
More »

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Current Issues
View the Current Issue
HemOnc Today